Methotrexate
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Spondylarthropathies
Conditions
Spondylarthropathies, Spondylitis, Ankylosing
Trial Timeline
Mar 1, 2006 → —
NCT ID
NCT00298012About Methotrexate
Methotrexate is a approved stage product being developed by Orion Corporation for Spondylarthropathies. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00298012. Target conditions include Spondylarthropathies, Spondylitis, Ankylosing.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00298012 | Approved | Withdrawn |
Competing Products
3 competing products in Spondylarthropathies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Secukinumab | Novartis | Phase 3 | 77 |
| Etanercept | Pfizer | Approved | 84 |
| etoricoxib + Other COX-2 inhibitor + nsNSAIDs | Organon | Pre-clinical | 18 |